Format

Send to

Choose Destination
J Cardiol Cases. 2018 Feb 9;17(5):178-181. doi: 10.1016/j.jccase.2018.01.004. eCollection 2018 May.

Limited effects of long-term enzyme replacement therapy on the cardiac conduction system in Fabry disease.

Author information

1
Department of Internal Medicine, Komatsu Municipal Hospital, Komatsu, Japan.
2
Division of Diagnostic Pathology, Komatsu Municipal Hospital, Komatsu, Japan.
3
Division of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Komatsu, Japan.

Abstract

The long-term effects of enzyme replacement therapy (ERT) on cardiac function and the conduction system in Fabry disease are not clearly understood. We report a case of a 48-year-old man with non-classical Fabry disease treated with ERT for 11 years. He was diagnosed with Fabry disease at age 27 years based on the presence of decreased alpha-galactosidase A activity in the peripheral leukocytes and of the causal alpha-galactosidase A mutation (Val339Gln). Subsequently, peritoneal dialysis was initiated for renal failure at age 35 years. ERT was initiated at age 39 years to halt the progression of cardiac dysfunction. Electrical conduction disturbances progressed gradually to complete atrioventricular block with atrial standstill during 9 years of ERT despite the lack of progression of ventricular hypertrophy. Although he underwent permanent pacemaker implantation to prevent sudden cardiac death, the atrioventricular junctional rhythm remained, thereby lowering the ventricular pacing rate. Based on this case, we recognize that the effects of ERT are limited for inhibiting the progression of Fabry disease and especially for inhibiting arrhythmia and conduction disturbances. Early diagnosis of Fabry disease and early initiation of ERT might be the key to further improvements in this disease and its associated conditions. <Learning objective: We encountered a patient with Fabry disease treated with long-term enzyme replacement therapy (ERT) in whom conduction disturbances progressed without progression of left ventricular hypertrophy. This case suggests that ERT is limited for inhibiting the progression of Fabry disease and especially of arrhythmia and conduction disturbances. Early diagnosis of Fabry disease and initiation of ERT may be important for providing further improvements of this condition.>.

KEYWORDS:

Cardiac pacemaker implantation; Enzyme replacement therapy; Fabry disease

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center